Objective: In our study, we aimed to investigate the prevalence of rotavirus and enteric adenovirus in stool samples sent to our laboratory for antigen detection of children between 0-18 years of age admitted to hospital with diarrhea, abdominal pain, vomiting and fever and diagnosed as gastroenteritis. We also analyzed their frequencies according to demographic parameters. Methods: Results of 5156 pediatric patients admitted to Necmettin Erbakan University Meram Faculty of Medicine Hospital and diagnosed as gastroenteritis between January 2013-December 2015 were investigated retrospectively. VIKIA ® RotaAdeno (bioMérieux, Marcy l'Etoile, France), a chromatographic immunoassay detecting both viruses simultaneously was used according to the manufacturer's recommendations in stool samples. Results: Viral antigens were detected in 884 (17.1%) of the total 5156 samples. 764 (14.8%) of the positive results were detected as rotavirus and 120 (2.3%) were detected as adenovirus. Of the patients with positive results, 412 (46.6%) were female and 472 (53.4%) were male. When results are considered according to age, 2-4 age group was found to have the most common positivity (n=372) as 42.1%. Seasonal distribution of acute gastroenteritis cases was analyzed and the number of cases due to rotavirus was found to be increased in winter and spring and enteric adenoviruses were detected all year round. Conclusions: Rotavirus is the most common reason of gastroenteritis in the newborn and children, which must be considered for patients with diarrhea especially in the first four years of life. Rapid diagnosis is important for prediction of clinical implications and treatment. As enteric adenovirus is an important reason of gastroenteritis in infancy and childhood, it is necessary to investigate adenovirus antigens as well. Conducting regional studies are important for contributing to epidemiological data. Klimik Dergisi 2016; 29(3): 121-4.
Objective: Rubella virus causes intrauterin infections in pregnant women and it is teratogenic for fetus. Detecting sensitivity for Rubella virus by screening tests before or during pregnancy is important for preventing unwanted fetal and perinatal infections. In this study, women of childbearing age who admitted to Necmettin Erbakan University Meram Medical Faculty were analyzed retrospectively for rubella seropositivity according to the distribution of age groups. Material and Methods: Materials and methods: Rubella IgG antibody levels of 2151 women who were admitted to various clinics in our hospital between 1 January 2013-31 December 2015 were determined by ELFA method and investigated by separating into age groups. Results: Of the women, 567 were (26.3%) found to be in 18-25 age group, 1143 (53.6%) were in 26-35 age group and 441 were (20.5%) in 36-45 age group. In women's age groups of 18-25, 26-35 and 36-45 years, the number of rubella IgG positivity and the rates were detected as 551 (97.1%), 1075 (94.0%) and 394 (89.4%) respectively. Of the total 2151 samples, 2020 (93.9%) were found to be positive for rubella IgG antibody. 1259 samples were sent from pregnancy clinics and 1169 (92.8%) of the samples were found to be positive for Rubella IgG. Conclusion: In our study rubella seroprevalence among women of childbearing age in Konya is found to be high. Ensuring immunity to rubella virus by increasing the rate of seropositivity in women of childbearing age before pregnancy will be effective in preventing congenital rubella infection. It is pleasant that there is high immunity in our province but women who are seronegative should be detected and should be vaccinated before pregnancy for preventing congenital infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.